New York State Teachers Retirement System Purchases Shares of 30,243 Amneal Pharmaceuticals, Inc. $AMRX

New York State Teachers Retirement System purchased a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 30,243 shares of the company’s stock, valued at approximately $376,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Kemnay Advisory Services Inc. purchased a new stake in Amneal Pharmaceuticals in the fourth quarter valued at approximately $26,000. Federated Hermes Inc. lifted its position in Amneal Pharmaceuticals by 1,680.6% during the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after purchasing an additional 2,168 shares during the last quarter. Comerica Bank grew its stake in Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after buying an additional 1,957 shares in the last quarter. Spire Wealth Management grew its stake in Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after buying an additional 1,023 shares in the last quarter. Finally, Transamerica Financial Advisors LLC increased its holdings in shares of Amneal Pharmaceuticals by 541.9% in the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after buying an additional 2,460 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Shares of Amneal Pharmaceuticals stock opened at $16.69 on Wednesday. Amneal Pharmaceuticals, Inc. has a 52-week low of $7.66 and a 52-week high of $17.86. The company has a fifty day moving average of $14.80 and a 200-day moving average of $13.80. The stock has a market capitalization of $5.32 billion, a price-to-earnings ratio of 43.92 and a beta of 1.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Thursday, May 7th. The company reported $0.27 EPS for the quarter. The company had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. On average, equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Zacks Research cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Weiss Ratings lowered Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. UBS Group started coverage on Amneal Pharmaceuticals in a report on Friday, April 17th. They issued a “buy” rating and a $19.00 price objective for the company. Finally, Barclays increased their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Amneal Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $15.80.

Insider Activity at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the sale, the director owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. The trade was a 27.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 17.30% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.